截至今天 (7/20) 為止,已經有約 115 人拿到【Classic TDD by Example: Refactoring to Design】的影片跟教材了,上個週末也有許多人開始練習與發問,也同時在線上跟我分享一些他們感覺到最大不一樣的部份。
目前最多得是:
1. 沒想到拿到需求到開始動手寫程式(打開 IDE)之前,還有那麼多事情可以做,沒想到可以這樣做需求分析、驗收情境的分析、測試案例的整理與歸納。
2. 沒想到原來可以這樣寫程式,對比自己過去的開發習慣,根本是人家上太空,我們關門殺豬公。
3. 為什麼這麼合理的開發方式(從需求、到決定 input/output 與驗收方式,再到開發讓它能自動驗證是不是滿足目標了),以前不曾看過,也不曾嘗試過?真是相見恨晚。
註:目前還在【Google 表單預購】的優惠期 (優惠價 34000),7/24 之後就正式公開販售,屆時將回歸原價與一般折扣票種(34000~36000)。目前只先推出 C# 版本,其他語言的同學可以先照程序報名,但不影響未來票價(屆時一樣會有封測、首購等 A/B testing、內部驗證與銷售 優惠期)
這是一門你得一練再練,練到像鬼滅之刃裡面的呼吸法,你平時就都是這樣在呼吸了,在打仗戰鬥時,才能把平時積累的爆發力,行雲流水地展現出來。
這堪稱我目前的職涯代表作,91 人格擔保,絕對物超所值。(不要在若干年後,才又覺得相見恨晚啊,人生苦短,你的青春應該浪費在更美好事物上,你應該讓你的開發工作,就像藝術一般呈現)
a/b testing example 在 91 敏捷開發之路 Facebook 的最讚貼文
趁著疫情在家期間,我已經將【Classic TDD by Example: Refactoring to Design】的 C# 版本培訓內容準備完成,經過約一週的 A/B testing 與內容調整(感謝前100位下單的朋友,幫忙做測試、給建議、提意見),目前已經調整到進入穩定的產能,以及較好的品質與體驗。
目前優先開放給之前有填寫 google form 表單的朋友,開始進行報名。(若您當時有填寫 google form 且語言選擇是 C# 的,應該會收到我今天寄出的主動通知信,若有興趣,可儘快報名卡位出貨順序)
#Google表單預購 優惠價為 NT$ 34,000,原價為 NT$ 36,000,預計為期一週,7/24 正式對外販售,將以原價以及相關票種折扣售票(介於 NT$ 34,000~36,000 之間)
若您不是使用 C#,但看得懂 C#,或是寫 Java 的同學,想要優先入手 C# 的版本也是可以的,屆時推出 Java 或其他語言版本時,我將提供超值的加購優惠價格給你。這主題內容,越早學會,越早能用在實務上,越早能得到它帶來的好處。
接下來預計推出的語言順序為:Java > Python > JavaScript > PHP ....
給自己的目標是期望在年底之前可以推出 Java 版本,但會不會突然被其他計畫打亂,就不敢肯定了,畢竟如果疫情趨緩,我還有這兩個月的企業客戶 coaching 檔期要還。
另外,也開放其他語言的朋友提前報名,(我不會請你提前繳費,提前報名也不影響屆時的票價,純粹是在你知道相關資訊與票價之後,你仍感興趣想報名,到時封測、A/B testing 我會主動邀請你,是否要先以更優惠的價格來參與封測,提供建議與 feedback)
出貨清單與狀態更新,請見:https://hackmd.io/@SYvyb1O4SLq8W6nvAQW5mw/ByVVUt86O
之前填寫 google 表單時的培訓介紹,以及授權條款內容,請見:https://tdd.best/courses/classic-tdd-by-example-video-training/
a/b testing example 在 A Nan MOSTA 阿男醫師の磨思塔 Facebook 的最佳貼文
因為有不少朋友建議我,將日前臉書上“武漢肺炎發生率與致死率的國際比較”一文翻譯成英文,所以,就以英文版再次和大家分享,也謝謝大家的批評指教。
International Comparison of Incidence and Mortality Rates of COVID-19
In the statistics of the COVID-19 collected and published by the World Health Organization (WHO), only the numbers of confirmed cases and deaths of COVID-19 of affected countries are available, without taking the population of each country into consideration. It will result in a biased assessment of the COVID-19 risk for each country.
Better data for international comparison is incidence rates, which refer to the number of confirmed COVID-19 cases (numerator) divided by the number of the population (denominator) of a given country. As shown in Table 1. the incidence rate per 100,000 population was highest in Italy, Korean, Iran, and China (>5.0 per 100,000) and much lower in Japan, US and Taiwan (<0.5 per 100,000).
The number of confirmed COVID-19 cases in each country is not only related to its population but also dependent on the coverage rate of the COVID-19 virus test. The confirmed case number and incidence rate are relatively low for those countries where only the severe cases were tested for COVID-19 virus; and they are much higher for countries where severe, moderate and mild cases were tested for the virus.
Once a country changes its policy of virus testing, for example of testing only those who are seriously ill, the number of the confirmed cases and incidence rate will drop sharply in a short period of time, but its case fatality rate will rise accordingly.
The case fatality rate is the proportion (percentage) of confirmed COVID-19 cases who died from the disease. Its numerator is the number of confirmed cases who died from the disease, and its denominator is the total number of confirmed cases. It is for sure that the case fatality rate will be higher if the analysis is limited to severe cases, and it will drop dramatically if the analysis also includes moderate and mild cases.
As shown in Table 2, the case fatality rates are the same for severe (5%), moderate (0.5%) and mild (0.1%) COVID-19 confirmed cases in countries A, B, and C are the same, but
the overall case fatality rates per 1,000 confirmed cases are significantly different among the country A, where only test the severe cases (41 per 1,000), country B where both severe and moderate cases are tested (14 per 1,000), and country C where test all severe, moderate and mild cases (8 per 1,000).
Among the countries with more than 1,000 confirmed cases in Table 1, the overall case-fatality rates in Italy, China and Iran were all exceeded 3.5%. Obviously, the severe cases account for a relatively large proportion of confirmed cases. The overall case-fatality rate for South Korea and Germany was only 0.8% and 0.1%, respectively, where the moderate and mild cases account for a relatively large proportion.
When we see a rapid decline in the number of confirmed cases with a soared case fatality rate, we must first pay attention to the change in the country's virus testing strategy. The Director-General of WHO recently stated that all countries should be cautious for the case fatality rate of COVID-19 is rising! The conclusion that the Director-General was biasedly made without taking the change in the virus testing strategy into consideration. He made the matter worse by causing unnecessary panic!
In addition to the virus-detection strategy, some other factors such as age, chronic disease status, and quality of medical care also affect the case fatality rate. For examples, the fatality rate will be low if the patients in the hospital for isolation treatment are mostly young people, without chronic disease, and receiving good cares. If most patients are old, with chronic disease, and receiving inadequate cares due to limited hospital resources and manpower, the case fatality rate will become high.